Proficio Capital Partners LLC Takes Position in Organon & Co. (NYSE:OGN)

Proficio Capital Partners LLC acquired a new stake in Organon & Co. (NYSE:OGN - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 26,393 shares of the company's stock, valued at approximately $394,000.

Other large investors have also modified their holdings of the company. Pacer Advisors Inc. increased its stake in Organon & Co. by 94,482.1% during the 4th quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock valued at $166,391,000 after purchasing an additional 11,140,388 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Organon & Co. by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company's stock worth $81,288,000 after buying an additional 82,220 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Organon & Co. by 0.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,333,703 shares of the company's stock worth $49,739,000 after buying an additional 10,652 shares in the last quarter. Private Management Group Inc. lifted its stake in Organon & Co. by 11.9% in the 4th quarter. Private Management Group Inc. now owns 2,119,288 shares of the company's stock worth $31,620,000 after purchasing an additional 225,420 shares in the last quarter. Finally, Weiss Asset Management LP acquired a new position in Organon & Co. during the third quarter worth $32,966,000. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Price Performance

Organon & Co. stock traded down $0.05 during mid-day trading on Friday, hitting $14.52. 1,866,865 shares of the company were exchanged, compared to its average volume of 2,538,684. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The business's 50 day simple moving average is $15.33 and its two-hundred day simple moving average is $16.24. The company has a market capitalization of $3.74 billion, a P/E ratio of 4.36, a PEG ratio of 0.90 and a beta of 0.76.

Remove Ads

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). The company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were issued a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.72%. Organon & Co.'s payout ratio is 33.63%.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Morgan Stanley decreased their target price on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research note on Friday, February 14th. TD Cowen raised Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. Finally, Barclays reduced their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $20.80.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.